ARGNF
Price
$562.00
Change
+$11.04 (+2.00%)
Updated
May 12 closing price
Capitalization
35.31B
SLS
Price
$1.61
Change
-$0.02 (-1.23%)
Updated
Jun 6 closing price
Capitalization
162.64M
60 days until earnings call
Interact to see
Advertisement

ARGNF vs SLS

Header iconARGNF vs SLS Comparison
Open Charts ARGNF vs SLSBanner chart's image
Argen X
Price$562.00
Change+$11.04 (+2.00%)
Volume$10
Capitalization35.31B
SELLAS Life Sciences Group
Price$1.61
Change-$0.02 (-1.23%)
Volume$2.43M
Capitalization162.64M
ARGNF vs SLS Comparison Chart
Loading...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGNF vs. SLS commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGNF is a Hold and SLS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (ARGNF: $562.00 vs. SLS: $1.78)
Brand notoriety: ARGNF and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGNF: 269% vs. SLS: 120%
Market capitalization -- ARGNF: $35.31B vs. SLS: $162.64M
ARGNF [@Biotechnology] is valued at $35.31B. SLS’s [@Biotechnology] market capitalization is $162.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGNF’s FA Score shows that 1 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • ARGNF’s FA Score: 1 green, 4 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGNF is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLS’s TA Score shows that 4 TA indicator(s) are bullish.

  • SLS’s TA Score: 4 bullish, 4 bearish.

Price Growth

ARGNF (@Biotechnology) experienced а 0.00% price change this week, while SLS (@Biotechnology) price change was +4.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

SLS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGNF($35.3B) has a higher market cap than SLS($163M). SLS YTD gains are higher at: 71.154 vs. ARGNF (-13.850). ARGNF has higher annual earnings (EBITDA): 105M vs. SLS (-31.51M). ARGNF has more cash in the bank: 3.38B vs. SLS (13.9M). SLS has less debt than ARGNF: SLS (1M) vs ARGNF (39.1M). ARGNF has higher revenues than SLS: ARGNF (2.19B) vs SLS (0).
ARGNFSLSARGNF / SLS
Capitalization35.3B163M21,656%
EBITDA105M-31.51M-333%
Gain YTD-13.85071.154-19%
P/E Ratio34.27N/A-
Revenue2.19B0-
Total Cash3.38B13.9M24,309%
Total Debt39.1M1M3,906%
FUNDAMENTALS RATINGS
ARGNF vs SLS: Fundamental Ratings
ARGNF
SLS
OUTLOOK RATING
1..100
9521
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
10100
SMR RATING
1..100
51100
PRICE GROWTH RATING
1..100
6136
P/E GROWTH RATING
1..100
89100
SEASONALITY SCORE
1..100
7050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLS's Valuation (57) in the Biotechnology industry is in the same range as ARGNF (74) in the null industry. This means that SLS’s stock grew similarly to ARGNF’s over the last 12 months.

ARGNF's Profit vs Risk Rating (10) in the null industry is significantly better than the same rating for SLS (100) in the Biotechnology industry. This means that ARGNF’s stock grew significantly faster than SLS’s over the last 12 months.

ARGNF's SMR Rating (51) in the null industry is somewhat better than the same rating for SLS (100) in the Biotechnology industry. This means that ARGNF’s stock grew somewhat faster than SLS’s over the last 12 months.

SLS's Price Growth Rating (36) in the Biotechnology industry is in the same range as ARGNF (61) in the null industry. This means that SLS’s stock grew similarly to ARGNF’s over the last 12 months.

ARGNF's P/E Growth Rating (89) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that ARGNF’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLS
RSI
ODDS (%)
Bearish Trend 12 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
90%
Momentum
ODDS (%)
Bullish Trend 12 days ago
84%
MACD
ODDS (%)
Bullish Trend 12 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
85%
Declines
ODDS (%)
Bearish Trend 27 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
88%
Aroon
ODDS (%)
Bullish Trend 12 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ARGNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with SLS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGNF
1D Price
Change %
ARGNF100%
N/A
SLS - ARGNF
36%
Loosely correlated
-7.77%
RLMD - ARGNF
31%
Poorly correlated
+9.50%
TPST - ARGNF
27%
Poorly correlated
+1.94%
GNNSF - ARGNF
23%
Poorly correlated
N/A
CVALF - ARGNF
23%
Poorly correlated
-4.41%
More

SLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with AKRO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
-7.77%
AKRO - SLS
44%
Loosely correlated
-1.48%
ARGNF - SLS
36%
Loosely correlated
N/A
SABS - SLS
32%
Poorly correlated
-1.12%
ETNB - SLS
29%
Poorly correlated
+0.76%
LPTX - SLS
28%
Poorly correlated
+2.36%
More